GlassScriptPhysician profile
Kristopher Michael Mcdonough
NPI 1851412779
$461,143.51
in general payments reported to CMS, 2019-2025
47 companies · $80K in 2025
The $80K reported for 2025 was more than what 98% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $34K · 2021: $63K · 2022: $52K · 2023: $123K · 2024: $95K · 2025: $80K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $234K · Education: $48K · Travel and Lodging: $8,466 · Food and Beverage: $7,982.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $234,175.00 |
| Education | $48,000.00 |
| Travel and Lodging | $8,465.89 |
| Food and Beverage | $7,982.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $354,329.62 | 2019-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Intuitive Surgical, INC. | $80,323.18 | 2021-2025 | Da Vinci Surgical System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22,216.13 | 2019-2023 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $812.55 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Mallinckrodt Hospital Products INC. | $272.86 | 2020-2025 | Acthar |
| Philips North America LLC | $201.19 | 2019-2023 | |
| Medtronic, INC. | $198.53 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $181.26 | 2021-2024 | Dupixent |
| Amgen INC. | $175.50 | 2021-2025 | Tezspire |
| Ceribell, INC. | $151.51 | 2024 | Pocket Eeg Device |
| Genzyme Corporation | $146.95 | 2019-2025 | |
| Electromed, INC. | $139.98 | 2021-2023 | Smartvest |
| Pulmonx Corporation | $127.42 | 2023-2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Janssen Pharmaceuticals, INC | $124.49 | 2019 | |
| Merck Sharp & Dohme LLC | $112.09 | 2022-2025 | Keytruda, Dificid, Zerbaxa |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristopher Mcdonough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.